Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.
about
Extensive Intestinal Resection Triggers Behavioral Adaptation, Intestinal Remodeling and Microbiota Transition in Short Bowel SyndromeChanges in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeabilityGut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.Intestinal mucosal adaptation.GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.Animal models of gastrointestinal and liver diseases. Animal models of infant short bowel syndrome: translational relevance and challenges.High-fat diet enhances villus growth during the adaptation response to massive proximal small bowel resection.Glucagon-like peptide-2-stimulated protein synthesis through the PI 3-kinase-dependent Akt-mTOR signaling pathway.Ret heterozygous mice have enhanced intestinal adaptation after massive small bowel resection.Recent advances in small bowel diseases: Part II.New growth factor therapies aimed at improving intestinal adaptation in short bowel syndrome.Enhanced Ghrelin Levels and Hypothalamic Orexigenic AgRP and NPY Neuropeptide Expression in Models of Jejuno-Colonic Short Bowel Syndrome.Morphological, kinetic, membrane biochemical and genetic aspects of intestinal enteroplasticityEarly but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion.A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patientsGrowth factors: possible roles for clinical management of the short bowel syndrome.Nonruminant Nutrition Symposium: The role of glucagon-like peptide-2 in controlling intestinal function in human infants: regulator or bystander?Short bowel syndrome in children: current and potential therapies.Review article: a comparison of glucagon-like peptides 1 and 2.The role of growth factors in intestinal regeneration and repair in necrotizing enterocolitis.On the horizon: trophic peptide growth factors as therapy for neonatal short bowel syndrome.Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats.Wnt/β-catenin signaling cascade down-regulation following massive small bowel resection in a rat.The role of the BMP signaling cascade in regulation of stem cell activity following massive small bowel resection in a rat.Accelerated intestinal epithelial cell turnover after bowel resection in a rat is correlated with inhibited hedgehog signaling cascade.Glucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonates.Potential Hormone Mechanisms of Bariatric Surgery.The effect of glucagon-like Peptide-2 receptor agonists on colonic anastomotic wound healing.Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.Role of glucagon-like peptide-2 deficiency in neonatal short-bowel syndrome using neonatal piglets.Role of Incretin Axis in Inflammatory Bowel Disease.Synergy of glucagon-like peptide-2 and epidermal growth factor coadministration on intestinal adaptation in neonatal piglets with short bowel syndrome.Glucagon-like peptide-2 in umbilical cord blood from mature infants.Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure
P2860
Q28076717-E57B3EE0-55CF-476D-926B-9985DDC6963BQ29617378-82B9BACA-750E-455D-81FC-1476BF9A419AQ33865971-3FF65FF7-4980-48A8-8218-CA31593BD909Q33867801-93A2511A-0BDE-49DA-923D-BE37817F07F9Q34494154-AFB82549-624F-4FB5-A357-DE833BD07ABAQ34726758-D33195BF-0D32-4523-B7FE-85129FEFEA38Q35538194-C82117A3-0356-4C4E-9656-B628B0C17360Q35756432-53BB8A56-00D2-488C-A55C-4440D415C6C0Q35994078-09D6BE91-6627-4ACF-9C15-2C43C41015D3Q36093336-F9C0675E-C56F-4F4E-AFF2-76DD35F4424BQ36489336-2AE2D4D3-1A70-4404-960E-3A61C68030E9Q37023794-A905FC63-B5FE-4D95-98F0-1534A4038E70Q37122381-A4D56D82-DAE7-4330-B0FD-41B168490CB7Q37138788-35E05931-D8C3-470D-BB7F-A2AD6614ED71Q37247764-FEE5F0F6-A11E-4744-80AD-7F0D2257E1D2Q37685500-0532AD24-48ED-4CAB-9EE2-A80A7210D76AQ37958506-78D3E938-C481-445F-8390-7A693BF48846Q37997502-328879CC-635D-4991-B364-FE60B6200CFAQ38057350-AD273222-0982-4957-94C6-78ED111FA9FAQ38101129-DF681A1A-447D-4C19-B4F3-1BCB07ED91F8Q38711705-18021FCF-532E-44B6-8BDD-9F695AF82704Q39974508-B713E970-23CA-4C27-9B78-C18748D0657AQ40159834-52DA40F4-3204-4FDC-B03C-DED0B46B7E4EQ40325324-64A4A697-5130-449C-A157-8D19DAD2A1D9Q40406037-A1FA87CE-E2BF-4FDA-98B8-AD5DC7B0FEA9Q41393541-13389E0E-36EC-4AC6-84D2-320D62835FF1Q41625381-97658740-FAEA-4EF9-86A4-8BEF41C49BC5Q41873272-8A0AAE7D-6BD2-4C5C-95C5-B66522EB4A63Q43263384-07716439-C4D2-4A1B-BBA6-64BA1D394DFEQ46408838-0F7431C3-9FF6-4EEF-821F-B0074D6CD38AQ47103249-9F39E331-6927-47A1-8004-A06BB49FD37EQ48333324-D8195706-88E6-4860-A2FA-5C8106D985AAQ51476113-8EB276F7-FE85-41E8-AA50-47C2D5CD18EFQ58447452-1B81C66D-1AE8-4263-BEFF-7A464B88FC28
P2860
Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Nutrient-stimulated GLP-2 rele ...... rimental short bowel syndrome.
@en
Nutrient-stimulated GLP-2 rele ...... rimental short bowel syndrome.
@nl
type
label
Nutrient-stimulated GLP-2 rele ...... rimental short bowel syndrome.
@en
Nutrient-stimulated GLP-2 rele ...... rimental short bowel syndrome.
@nl
prefLabel
Nutrient-stimulated GLP-2 rele ...... rimental short bowel syndrome.
@en
Nutrient-stimulated GLP-2 rele ...... rimental short bowel syndrome.
@nl
P2093
P2860
P356
P1476
Nutrient-stimulated GLP-2 rele ...... erimental short bowel syndrome
@en
P2093
P2860
P304
P356
10.1152/AJPGI.00242.2004
P577
2004-09-23T00:00:00Z